Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 9/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | JAK3 | P52333 | 6/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1292918 | 0.89 | PTK2 (0.63) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL692967 | 0.88 | PTK2 (0.73) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL22174998 | 0.88 | PTK2 (0.62) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL691964 | 0.88 | MAPK1 (0.63) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL690300 | 0.88 | PTK2 (0.75) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| Gsk-2256098 SCHEMBL29361345 | 0.88 | PTK2 (1.00) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| Gsk-2256098 SCHEMBL691518 | 0.88 | PTK2 (1.00) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL691054 | 0.88 | PTK2 (0.61) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| Gsk-2256098 SCHEMBL691552 | 0.87 | PTK2 (0.98) | PTK2MAPK1MAPK3MAPK10MAPK9 | |
| SCHEMBL30759530 | 0.87 | PTK2 (0.74) | PTK2MAPK1MAPK3MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | claimed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | claimed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | claimed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | claimed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | claimed |
| US-11564927-B2 | Therapeutic compositions, combinations, and methods of use | VERASTEM, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3904351-A1 | FAK INHIBITOR AND DRUG COMBINATION THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-02-04 | — | — | US | disclosed |
| US-20200330471-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | RGCM SA LLC, AS PURCHASER AGENT | 2020-10-22 | — | — | US | disclosed |
| WO-2020135442-A1 | FAK INHIBITOR AND DRUG COMBINATION THEREOF | 成都海创药业有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564927-B2 | Therapeutic compositions, combinations, and methods of use | PTK2, CD274, PDCD1LG2 | PTK2 1/4885MAPK1 688/4885MAPK3 891/4885 |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | CD274, PDCD1, PDCD10 | PTK2 4571/4885MAPK1 2026/4885MAPK3 3956/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | CD274, PDCD1, PTK2 | PTK2 3/4885MAPK1 35/4885MAPK3 230/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20200330471-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CD274, PDCD1LG2 | PTK2 1/4885MAPK1 688/4885MAPK3 891/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885MAPK3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.